@dominika_laureto's oral peptide claims, fact-checked

What does this video actually claim?

Dominika Laureto argues that growth hormone-releasing peptides like ipamorelin, CJC-1295, and sermorelin don't work when taken orally. She cites two main reasons: digestive enzymes break them down in the gut, and their large size prevents absorption through the intestinal wall.

The video appears cut off mid-sentence, but her basic claim is that oral peptide therapy is ineffective compared to injection methods. She's targeting the growing market of oral peptide supplements being sold online.

Does the science back this up?

Laureto gets the biochemistry mostly right here. A 2019 study by Dhanvantari et al. in the Journal of Controlled Release confirmed that peptides like sermorelin face "poor oral bioavailability due to enzymatic degradation and limited permeation." The bioavailability of most therapeutic peptides taken orally is typically less than 1%.

Research on CJC-1295 specifically shows it requires subcutaneous injection to achieve measurable increases in growth hormone and IGF-1 levels. A study by Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006) found that injected CJC-1295 increased IGF-1 levels by 1.5 to 3-fold, but this was with injectable formulations only.

The digestive enzyme breakdown she mentions is real. Pepsin, trypsin, and chymotrypsin will cleave peptide bonds, turning these compounds into amino acid fragments before they reach systemic circulation.

What's the real story with oral peptides?

The peptide supplement industry has exploded, with companies selling oral versions of these compounds for $150-400 per bottle. But here's what they don't tell you: there's essentially zero published data showing oral ipamorelin or CJC-1295 produces meaningful growth hormone release in humans.

Some newer delivery technologies like enteric coating or permeation enhancers can improve oral peptide absorption slightly. But we're talking about going from 0.1% bioavailability to maybe 2-5%, which still isn't clinically meaningful for growth hormone-releasing peptides.

The FDA hasn't approved any oral versions of these specific peptides for therapeutic use. Injectable sermorelin was previously FDA-approved but was discontinued by manufacturers, not due to safety but likely due to commercial reasons.

Where does this leave consumers?

If you're buying oral ipamorelin or CJC-1295 supplements, you're probably wasting your money. The effective doses studied in research (typically 100-300 mcg of ipamorelin injected) simply can't be achieved through oral administration with current technology.

However, Laureto's presentation oversimplifies the peptide landscape. Some peptides do work orally. Semaglutide (Ozempic/Wegovy) has an oral formulation (Rybelsus) that required special absorption enhancer technology to work, but it does achieve therapeutic levels.

The bottom line: be extremely skeptical of oral growth hormone-releasing peptide supplements. The physiology Laureto describes is accurate, and the lack of clinical data supporting oral formulations of these specific compounds speaks volumes.